Russell Investments Group Ltd. Raises Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

Russell Investments Group Ltd. increased its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 152.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,115 shares of the company’s stock after purchasing an additional 3,696 shares during the period. Russell Investments Group Ltd.’s holdings in BeiGene were worth $1,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in BGNE. Rockefeller Capital Management L.P. increased its holdings in BeiGene by 8.3% in the third quarter. Rockefeller Capital Management L.P. now owns 885 shares of the company’s stock valued at $119,000 after buying an additional 68 shares in the last quarter. Engineers Gate Manager LP purchased a new position in BeiGene in the third quarter valued at $230,000. Advisors Asset Management Inc. increased its holdings in BeiGene by 26.7% in the first quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company’s stock valued at $235,000 after buying an additional 262 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in BeiGene by 8.5% in the third quarter. Janney Montgomery Scott LLC now owns 1,895 shares of the company’s stock valued at $255,000 after buying an additional 149 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in BeiGene in the third quarter valued at $310,000. Hedge funds and other institutional investors own 51.43% of the company’s stock.

Analyst Upgrades and Downgrades

BGNE has been the subject of a number of recent analyst reports. Morgan Stanley cut their price objective on shares of BeiGene from $325.00 to $321.00 and set an “overweight” rating for the company in a report on Tuesday, February 28th. Bank of America boosted their target price on shares of BeiGene from $230.10 to $263.30 and gave the stock a “neutral” rating in a research note on Wednesday, April 12th. StockNews.com began coverage on shares of BeiGene in a research note on Thursday, May 18th. They set a “hold” rating for the company. Guggenheim restated a “buy” rating and set a $350.00 price target on shares of BeiGene in a research report on Tuesday, February 28th. Finally, Cowen boosted their target price on shares of BeiGene from $213.00 to $262.00 and gave the company an “outperform” rating in a report on Tuesday, February 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $289.16.

BeiGene Trading Down 1.2 %

Shares of BGNE stock opened at $236.50 on Thursday. The business’s 50 day moving average is $240.47 and its two-hundred day moving average is $230.66. BeiGene, Ltd. has a twelve month low of $120.94 and a twelve month high of $280.62. The company has a market capitalization of $22.63 billion, a P/E ratio of -12.73 and a beta of 0.80. The company has a current ratio of 3.75, a quick ratio of 3.51 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($3.34) EPS for the quarter, beating the consensus estimate of ($3.66) by $0.32. The business had revenue of $447.80 million during the quarter, compared to analysts’ expectations of $449.44 million. BeiGene had a negative return on equity of 41.58% and a negative net margin of 123.48%. The company’s quarterly revenue was up 46.1% compared to the same quarter last year. During the same period last year, the firm earned ($4.24) EPS. Equities analysts forecast that BeiGene, Ltd. will post -12.56 EPS for the current year.

Insiders Place Their Bets

In other BeiGene news, COO Xiaobin Wu sold 7,000 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $253.72, for a total transaction of $1,776,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Xiaobin Wu sold 7,000 shares of BeiGene stock in a transaction on Monday, May 8th. The stock was sold at an average price of $253.72, for a total value of $1,776,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Xiaodong Wang sold 67,635 shares of BeiGene stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $226.03, for a total value of $15,287,539.05. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by company insiders.

BeiGene Company Profile

(Get Rating)

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.